Ipamorelin: Selective GH Secretagogue Research Profile

Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue receptor agonist. First described by Raun et al. in 1998, it rapidly became a widely used research tool for investigating GHS-R1a receptor pharmacology due to its exceptional receptor selectivity compared to earlier GHRP compounds.

Chemical and Molecular Data

Structural Design and Metabolic Stability

Ipamorelin incorporates three non-natural amino acid modifications that collectively contribute to its research utility.

Aib at position 1 (alpha-aminoisobutyric acid). Aib is a non-proteinogenic amino acid that resists enzymatic degradation by dipeptidyl peptidase IV (DPP-IV), the enzyme responsible for rapid inactivation of many regulatory peptides. Aib also tends to adopt alpha-helical conformations, influencing receptor binding geometry.

D-2-Naphthylalanine (D-2-Nal) at position 3. The D-configuration provides resistance to L-specific amino acid oxidases and many endopeptidases. The bulky naphthyl side chain contributes to GHS-R1a binding affinity.

D-Phenylalanine (D-Phe) at position 4. D-configuration for metabolic stability. This position in GH secretagogue peptides has been extensively studied in SAR research for its role in receptor selectivity.

C-terminal amidation (Lys-NH2). Prevents carboxypeptidase degradation, extending metabolic stability.

GHS-R1a Receptor Pharmacology

The growth hormone secretagogue receptor type 1a (GHS-R1a) is a Gq/11-coupled GPCR expressed predominantly in the hypothalamus and pituitary. Activation leads to phospholipase C activation, IP3-mediated calcium release, and PKC activation.

A defining characteristic of Ipamorelin versus earlier GHRPs (GHRP-2, GHRP-6, Hexarelin) is its selectivity. Functional assays have demonstrated that Ipamorelin activates GHS-R1a with minimal cross-reactivity at ACTH receptors, prolactin pathways, and aldosterone secretion pathways, making it a cleaner tool for isolated GHS-R1a biology research.

Growth Hormone Axis Research

In animal model studies, Ipamorelin has been used to investigate GH axis dynamics. It preserves physiological pulsatile GH secretion patterns, contrasting with CJC-1295 (With DAC), which produces sustained GH elevation, enabling comparison of pulsatile versus sustained stimulation paradigms. Preclinical rat model studies have also examined effects on tibial bone growth plate activity, a classic endpoint in GH axis research.

Research Applications

Ipamorelin is used in GHS-R1a binding and receptor pharmacology studies, GH axis signalling research, structure-activity relationship (SAR) studies of GH secretagogues, comparative receptor selectivity assays, and combined GH axis research alongside CJC-1295 (No DAC).

Storage and Handling

Store at -20 degrees C in a desiccated environment, protected from light and moisture. Reconstitute with bacteriostatic water. Non-natural amino acids contribute to excellent stability in lyophilised form. Avoid repeated freeze-thaw cycles.

Comparison: Ipamorelin vs Other GH Secretagogues

Frequently Asked Questions

Why is Ipamorelin considered more selective than earlier GHRPs?
Earlier growth hormone releasing peptides such as GHRP-2 and Hexarelin activate GHS-R1a but also trigger release of ACTH (leading to cortisol elevation) and prolactin, which complicates their use as isolated GHS-R1a research tools. Ipamorelin demonstrates minimal activity at these secondary pathways in functional assay data, making it a cleaner pharmacological tool for studying GHS-R1a biology in isolation.

What is the difference between Ipamorelin and CJC-1295 in GH research?
Ipamorelin acts at GHS-R1a (the ghrelin receptor), activating GH release via IP3/Ca2+ and PKC pathways. CJC-1295 acts at GHRHR (the GHRH receptor), activating GH release via cAMP/PKA. These two receptors are complementary and synergistic — both are expressed on pituitary somatotrophs and their combined activation has been studied for additive GH release effects. This makes them frequently paired in dual-receptor GH axis research designs.

Does Ipamorelin bind albumin?
No. Ipamorelin has a short plasma half-life (approximately 2 hours) and does not incorporate a fatty acid or DAC group for albumin binding. This contrasts with CJC-1295 (With DAC), which achieves an approximately 8-day half-life through covalent albumin binding, and Semaglutide which achieves approximately 7 days through non-covalent fatty acid-albumin interaction.

What is the reconstitution protocol for Ipamorelin?
Reconstitute Ipamorelin lyophilised powder with bacteriostatic water. Store lyophilised at -20°C. Once reconstituted, store at 4°C and use within a short timeframe. Avoid repeated freeze-thaw cycles. The non-natural amino acids (Aib, D-forms) contribute to improved stability compared to native GHRP sequences.

For laboratory and analytical research purposes only. Not for human or veterinary use. No dosage or administration guidance is provided or implied.

Related research peptides: CJC-1295 (No DAC) | CJC-1295 (With DAC) | BPC-157 | Retatrutide

View Ipamorelin product page